Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
Moderna partners with gene-editing company Metagenomi
by Ryan Cross
November 6, 2021
| A version of this story appeared in
Volume 99, Issue 41
Moderna, known for its messenger RNA (mRNA) vaccines for COVID-19, is branching out into gene editing. Moderna has struck a research collaboration with Metagenomi, a start-up focused on discovering new enzymes for CRISPR gene editing and other gene-editing systems. The companies will encode the systems in mRNA molecules and package the molecules in Moderna’s lipid nanoparticles to treat genetic diseases. Metagenomi will get an undisclosed payment and investment from Moderna.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X